Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 MillionBusiness Wire • 04/25/23
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious DiseasesBusiness Wire • 04/17/23
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial VirusBusiness Wire • 04/06/23
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)Business Wire • 04/05/23
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral ResearchBusiness Wire • 03/14/23
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceBusiness Wire • 03/07/23
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 02/07/23
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ETBusiness Wire • 02/07/23
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma ConferenceBusiness Wire • 02/07/23
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022Business Wire • 01/31/23
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/23
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/23
Enanta Pharmaceuticals to Participate in Two Investor Conferences in NovemberBusiness Wire • 11/22/22
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 11/21/22
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETBusiness Wire • 11/21/22
Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022Business Wire • 11/14/22
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19Business Wire • 11/09/22
Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022Business Wire • 10/19/22
Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial VirusBusiness Wire • 10/17/22
Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial VirusBusiness Wire • 10/03/22
Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV SymposiumBusiness Wire • 09/29/22
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV SymposiumBusiness Wire • 09/22/22
New Preclinical Data for EDP-235, Enanta's Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022Business Wire • 09/07/22
